ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes
Abstract Background Venetoclax (VEN) in combination with hypomethylating agents has emerged as a pivotal therapy for elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, monocytic AML exhibit greater resistance to VEN-based regimens compared to non-monocytic...
Sparad:
| Huvudupphov: | , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMC
2025-11-01
|
| Serie: | BMC Cancer |
| Ämnen: | |
| Länkar: | https://doi.org/10.1186/s12885-025-15272-9 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|